News
Training for Me “The Dispensary Manager”
In-house training HERE
Early Bird Offer: Don’t miss out!!
CLICK HERE TO BOOK LIMITED OFFER: Book by the 19th May for only £175pp (members) or £250pp (non-members)! Dispex is thrilled to invite you to our upcoming full day training...
Practice Retention and Recruitment
By Dispex There are numerous reasons why we’re witnessing an increasing number of practices struggling to retain and replace various job roles. Primary care is under immense pressure following another...
Six new community diagnostic centres to deliver more than 500,000 lifesaving checks a year
Source: Department of Health and Social Care, NHS England, The Rt Hon Steve Barclay MP, and The Rt Hon Rishi Sunak MP 15th May 2023 Tens of thousands of patients across the country are...
Delivery plan for recovering access to primary care -Access all areas by Paula the PM
Source: Practice Index by Paula the PM This week, NHSE have released their Delivery plan for recovering access to primary care along with a covering letter. Well, dear readers, I’ve waded through it,...
Care Quality Commission: An update on our plan and approach for transformation
Source: The CQC 19.4.23 We’re making good progress against the plan we set out in December 2022. However, this remains a complex transformation programme and a key part of our approach...
Risk Management
Dispex SOP We are pleased to inform our members that we have updated our Risk Management SOP (DPX-QC5). The purpose of the SOP is to enable you and your team...
Dispensing and the drive for environmental sustainability
Assessment of Long-Acting Beta Agonists (LABAs) We continue our journey to transform Respiratory care to the lowest possible carbon impact by looking at LABAs this month. Chlorofluorocarbons (CFCs) inhaler propellants...
Class 3 Medicines Recall: Hikma Farmacêutica Portugal S.A., Gemcitabine 1g/26.3ml & 2g/52.6ml Solution For Infusion Vial, EL(23)A/16
Source: MHRA /Gov.uk 10th May 2023 Hikma Farmacêutica Portugal S.A has informed the MHRA of a potential issue impacting the batches listed in this notification. MDR number MDR 002-05/23 Company...
National Patient Safety Alert: Class 1 Medicines Recall Notification: Recall of Emerade 500 micrograms and Emerade 300 micrograms auto-injectors, due to the potential for device failure, NatPSA/2023/004/MHRA
Source: MHRA / Gov.uk Pharmaswiss Česka republika s.r.o. is initiating an urgent recall of all batches of Emerade 500 micrograms and Emerade 300 micrograms auto-injectors. National Patient Safety Alert Reference...
NHS Type 2 Diabetes Path to Remission Programme to treat obesity and type 2 diabetes
Source: NHS England The NHS and its partner Diabetes UK are delivering a new programme which provides a low calorie, total diet replacement treatment for people who are living with...
Out of Office
It’s that time of year again, when many of us eagerly anticipate our upcoming main holiday! Whether you’re fortunate enough to be going away or simply looking forward to time...
